Search Within

Andrew D Zelenetz

  1. "2002"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Radiation Oncology, Department of (4)
  6. Survivorship Research (4)

More Groups

People
  1. Craig Moskowitz (7)
  2. Jing Qin (7)
  3. Julie Feldstein (6)
  4. Gerard Donnelly (5)
  5. Raju Chaganti (5)
  6. Ariela Noy (4)

More People

Years
  1. 2002 (19)
Publications
  1. Blood (13)
  2. Genes Chromosomes and Cancer (1)
  3. Laboratory Investigation (1)
  4. Modern Pathology (1)
  5. Pharmacotherapy (1)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (1)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. American Association for Cancer Research (1)
  3. John Wiley & Sons (1)
  4. Lippincott Williams & Wilkins (1)
  5. Nature Publishing Group (1)
  6. Nature Research (1)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inhibition of VEGFR2 mediated paracrine pathways suppresses non-Hodgkin's lymphoma xenograft growth in NOD/SCID mice
    Meeting Abstract

    Wang, E. S.; Zhang, K.; O'connor, O.; Zhu, Z.; Hicklin, D.; Witte, L.; Zelenetz, A.; Rafii, S.; Moore, M. A. S.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • MUC-1 mucin protein expression correlates with advanced stage, adverse event free and overall survival in diffuse B-cell lymphoma
    Meeting Abstract

    Teruya-Feldstein, J.; Donnelly, G.; Goy, A.; Hegde, A.; Qin, J.; Filippa, D.; Gilles, F.; Zelenetz, A.; Houldsworth, J.; Chaganti, R. S. K.
    Modern Pathology (2002)

    Fulltext@MSK | Save
  • MUC-1 mucin protein expression correlates with advanced stage, adverse event free and overall survival in diffuse B-cell lymphoma
    Meeting Abstract

    Teruya-Feldstein, J.; Donnelly, G.; Goy, A.; Hegde, A.; Qin, J.; Filippa, D.; Gilles, F.; Zelenetz, A.; Houldsworth, J.; Chaganti, R. S. K.
    Laboratory Investigation (2002)

    Fulltext@MSK | Save
  • Increased chemotherapy dose attenuation in elderly patients: Evidence from surveys of practice patterns in early-stage breast cancer and non-Hodgkin's lymphoma
    Meeting Abstract

    Balducci, L.; Zelenetz, A. D.; Lyman, G. H.
    Pharmacotherapy (2002)

    Fulltext@MSK | Save
  • Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas
    Meeting Abstract

    O'Connor, O. A.; Moskowitz, C. H.; Wright, J. J.; Macgregor-Cortelli, B.; Straus, D.; Furst, D.; Horse-Grant, D.; Schenkein, D. P.; Zelenetz, A. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Clone specific PCR detects clonal cells after radiation therapy for early stage gastric MALT lymphoma
    Meeting Abstract

    Noy, A.; Yahalom, J.; Zaretsky, L.; Brett, I.; Zelenetz, A. D.
    Blood (2002)

    Fulltext@MSK | Save
  • An analysis of accelerated full course chemotherapy followed by upfront high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with International Prognostic Index IV (IPI IV) aggressive NHL
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Donnelly, G.; Zelenetz, A. D.; Noy, A.; Rice, D.; Kuznetsov, M.; Straus, D.; Nimer, S. D.; Portlock, C. S.
    Blood (2002)

    Fulltext@MSK | Save
  • Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT)
    Meeting Abstract

    Kewalramani, T.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S.; Qin, J.; Malhotra, S.; Yahalom, J.; Moskowitz, C. H.
    Blood (2002)

    Fulltext@MSK | Save
  • Autologous transplantation (ASCT) with total body irradiation (TBI) based conditioning appears superior to chemotherapy only (Non-TBI) conditioning for patients with relapsed or primary refractory chemosensitive (CS) diffuse large B-cell lymphoma (DLBCL) who have no extranodal sits (ENS) of disease (dz)
    Meeting Abstract

    Kewalramani, T.; Moskowitz, C. H.; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Nimer, S. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab [Bexxar (R)]
    Meeting Abstract

    Zelenetz, A. D.; Saleh, M.; Vose, J.; Younes, A.; Kaminski, M. S.
    Blood (2002)

    Fulltext@MSK | Save